PET with non-standard nuclides

Current Topics in Medicinal Chemistry

Volumn 10, Issue 11, 2010, Pages 1096-1112

  Hao, Guiyang ^a   Singh, Ajay N ^a   Liu, Wei ^a,b   Sun, Xiankai ^a,c  

^a Department of Radiology ^*  (United States)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Imaging probe; Immuno pet; Molecular imaging; Non standard pet nuclide; Pet; Radiation dosimetry; Radioimmunoconjugate

Indexed keywords

ARSENIC; BROMINE 76; BROMINE 77; COBALT 55; COPPER 60; COPPER 64; COPPER 67; GALLIUM 68; IODINE 124; RADIOISOTOPE; RUBIDIUM 82; TECHNETIUM 94M; UNCLASSIFIED DRUG; YTTRIUM 86; ZIRCONIUM 89;

ARTICLE; DRUG HALF LIFE; POSITRON EMISSION TOMOGRAPHY; RADIOIODINATION;

POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77955645499     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791384289     Document Type: Article

References (232)

1. Lide, D.R. Ed. Handbook of Chemistry and Physics, CRC Press, USA 2005.
2. Liu, X.; Laforest, R. Quantitative small animal PET imaging with nonconventional nuclides. Nucl. Med. Biol., 2009, 36(5), 551-559.
3. Laforest, R.; Liu, X. Image quality with non-standard nuclides in PET. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(2), 151-158.
4. Nayak, T.K.; Brechbiel, M.W. Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug. Chem., 2009, 20(5), 825-841.
5. Anderson, C.J.; Ferdani, R., Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. CancerBiother. Radiopharm., 2009, 24(4), 379-393.
6. Shokeen, M.; Anderson, C.J. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem.Res., 2009, 42(7), 832-841.
7. Herzog, H.; Tellmann, L.; Scholten, B.; Coenen, H.H.; Qaim, S.M. PET imaging problems with the non-standard positron emitters Yttrium-86 and Iodine-124. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(2), 159-165.
8. Hohn, A.; Zimmermann, K.; Schaub, E.; Hirzel, W.; Schubiger, P.A.; Schibli, R. Production and separation of ''non-standard'' PET nuclides at a large cyclotron facility: the experiences at the Paul Scherrer Institute in Switzerland. Q. J. Nucl. Med. Mol. Imaging, 2008, 52 (2), 145-150.
9. Qaim, S.M. Decay data and production yields of some non-standard positron emitters used in PET. Q. J. Nucl.Med. Mol. Imaging, 2008, 52(2), 111-120.
10. Tang, L. Radionuclide production and yields at Washington University School of Medicine. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(2), 121-133.
11. 73As for environmental studies. Appl. Radiat. Isot., 2007, 65(9), 1057-1064.
12. Jennewein, M.; Qaim, S.M.; Hermanne, A.; Jahn, M.; Tsyganov, E.; Slavine, N.; Seliounine, S.; Antich, P.A.; Kulkarni, P.V.; Thorpe, P.E.; Mason, R.P.; Rosch, F. A new method for radiochemical separation of arsenic from irradiated germanium oxide. Appl. Radiat. Isot., 2005, 63(3), 343-351.
13. Wilcke, O.; Brock, M. Positrocephalography. Results in 1,400 cases. Comparative study with angiography, pneumoencephalo-graphy and electroencephalography. Arq. Neuropsiquiatr, 1965, 23(4), 261-270.
14. Chattopadhyay, S.; Pal, S.; Vimalnath, K.V.; Das, M.K. A versatile technique for radiochemical separation of medically useful no-carrier-added (nca) radioarsenic from irradiated germanium oxide targets. Appl. Radiat.Isot., 2007, 65(11), 1202-1207.
15. Jennewein, M.; Lewis, M.A.; Zhao, D.; Tsyganov, E.; Slavine, N.; He, J.; Watkins, L.; Kodibagkar, V.D.; O'Kelly, S.; Kulkarni, P.; Antich, P.P.; Hermanne, A.; Rosch, F.; Mason, R.P.; Thorpe, P.E. Vascular imaging of solid tumors in rats with a radioactive arsenic- labeled antibody that binds exposed phosphatidylserine. Clin. Cancer Res., 2008, 14(5), 1377-1385.
16. Scholl, H.; Kloster, G.; Stocklin, G. Bromine-75-labeled 1,4-benzodiazepines: potential agents for the mapping of benzo-diazepine receptors in vivo: Concise Communication. J. Nucl. Med., 1983, 24(5), 417-422.
17. Maziere, B.; Loc'h, C. Use of bromine-76 and iodine-123 radiohalogenated tracers in the drug development process. Curr. Pharm. Des., 2001, 7(18), 1931-1943.
18. Mume, E.; Orlova, A.; Malmstrom, P.U.; Lundqvist, H.; Sjoberg, S.; Tolmachev, V. Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. Nucl. Med. Biol., 2005, 32(6), 613-622.
19. Lovqvist, A.; Lundqvist, H.; Lubberink, M.; Tolmachev, V.; Carlsson, J.; Sundin, A. Kinetics of Br-76-labeled anti-CEA antibodies in pigs; Aspects of dosimetry and PET imaging properties. Med. Phys., 1999, 26(2), 249-258.
20. Helfenbein, J.; Loc'h, C.; Bottlaender, M.; Emond, P.; Coulon, C.; Ottaviani, M.; Fuseau, C.; Chalon, S.; Guenther, I.; Besnard, J.C.; Frangin, Y.; Guilloteau, D.; Maziere, B. A selective radiobro-minated cocaine analogue for imaging of dopamine uptake sites: Pharmacological evaluation and PET experiments. Life Sci., 1999, 65(25), 2715-2726.
21. Cochen, V.; Ribeiro, M.J.; Nguyen, J.P.; Gurruchaga, J.M.; Villafane, G.; Loc'h, C.; Defer, G.; Samson, Y.; Peschanski, M.; Hantraye, P.; Cesaro, P.; Remy, P. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Movement Disorders, 2003, 18(8), 928-932.
22. Foged, C.; Halldin, C.; Loch, C.; Maziere, B.; Karlsson, P.; Maziere, M.; Swahn, C.G.; Farde, L. C-11- and Br-76-labelled NNC 22-0010, selective dopamine D-1 receptor radioligands for PET. Nucl. Med. Biol., 1996, 23(6), 837-844.
23. Kassiou, M.; Loc'h, C.; Bottlaender, M.; Mardon, K.; Ottaviani, M.; Coulon, C.; Katsifis, A.; Maziere, B. (+)-[(76) Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET. Nucl.Med. Biol., 2002, 29(3), 295-302.
24. Zhou, D.; Zhou, H.B.; Jenks, C.C.; Lewis, J.S.; Katzenellenbogen, J.A.; Welch, M.J. Bromination from the macroscopic level to the tracer radiochemical level: Br-76 radiolabeling of aromatic compounds via electrophilic substitution. Bioconjugate Chem., 2009, 20(4), 808-816.
25. Hoglund, J.; Orlova, A.; Sundin, A.; Lundqvist, H.; Tolmachev, V. Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated. Oncol. Rep., 2006, 16(1), 159-163.
26. Hoglund, J.; Tolmachev, V.; Orlova, A.; Lundqvist, H.; Sundin, A. Optimized indirect Br-76-bromination of antibodies using N-succinimidyl para-[Br-76]bromobenzoate for radioimmuno PET. Nucl. Med. Biol., 2000, 27(8), 837-843.
27. Lovqvist, A.; Sundin, A.; Ahlstrom, H.; Carlsson, J.; Lundqvist, H. 76Br-labeled monoclonal anti-CEA antibodies for radioimmuno positron emission tomography. Nucl. Med. Biol., 1995, 22(1), 125-131.
28. Lovqvist, A.; Sundin, A.; Ahlstrom, H.; Carlsson, J.; Lundqvist, H. Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. J. Nucl. Med., 1997, 38(3), 395-401.
29. Bruskin, A.; Sivaev, I.; Persson, M.; Lundqvist, H.; Carlsson, J.; Sjoberg, S.; Tolmachev, V. Radiobromination of monoclonal antibody using potassium [Br-76] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI). Nucl. Med. Biol., 2004, 31(2), 205-211.
30. Winberg, K.J.; Persson, M.; Malmstrom, P.U.; Sjoberg, S.; Tolmachev, V. Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [Br-76]undecahydrobromo-7,8-dicarba-nido-undecaborate (1-) ion. Nucl. Med. Biol., 2004, 31(4), 425-433.
31. Almutairi, A.; Rossin, R.; Shokeen, M.; Hagooly, A.; Ananth, A.; Capoccia, B.; Guillaudeu, S.; Abendschein, D.; Anderson, C.J.; Welch, M.J.; Frechet, J.M.J. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc. Natl. Acad. Sci. USA, 2009, 106(3), 685-690.
32. Bergstrom, M.; Lu, L.; Fasth, K.J.; Wu, F.; Bergstrom-Pettermann, E.; Tolmachev, V.; Hedberg, E.; Cheng, A.P.; Langstrom, B. In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. J. Nucl. Med., 1998, 39(7), 1273-1279.
33. Boni, R.; Blauenstein, P.; Dummer, R.; von Schulthess, G.K.; Schubiger, P.A.; Steinert, H.C. Non-invasive assessment of tumour cell proliferation with positron emission tomography and [Br-76]bromodeoxyuridine. Melanoma Res., 1999, 9(6), 569-573.
34. Borbath, I.; Gregoire, V.; Bergstrom, M.; Laryea, D.; Langstrom, B.; Pauwels, S. Use of 5-[Br-76]bromo-2 '-fIuoro-2 '-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29(1), 19-27.
35. Gardelle, O.; Roelcke, U.; Vontobel, P.; Crompton, N.E.A.; Guenther, I.; Blauenstein, P.; Schubiger, A.P.; Blattmann, H.; Ryser, J.E.; Leenders, K.L.; Kaser-Hotz, B. [Br-76]bromo-deoxyuridine PET in tumor-bearing animals. Nucl. Med. Biol., 2001, 28(1), 51-57.
36. Lu, L.; Bergstrom, M.; Fasth, K.J.; Langstrom, B. Synthesis of [Br-76]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats. J. Nucl. Med., 2000, 41(10), 1746-1752.
37. Kao, C.H.K.; Sassaman, M.B.; Szajek, L.P.; Ma, Y.; Waki, A.; Eckelman, W.C. The sequential syntheses of [Br-76]FBAU 3 ',5 '-dibenzoate and [Br-76]FBAU. J. Label. Compd. Rad., 2001, 44(13), 889-898.
38. Kiesewetter, D.O.; Jagoda, E.M.; Kao, C.H.K.; Ma, Y.; Ravasi, L.; Shimoji, K.; Szajek, L.P.; Eckelman, W.C. Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. Nucl. Med. Biol., 2003, 30(1), 11-24.
39. Parent, E.E.; Dence, C.S.; Jenks, C.; Sharp, T.L.; Welch, M.J.; Katzenellenbogen, J.A. Synthesis and biological evaluation of [F-18]bicalutamide, 4-[Br-76]bromobicalutamide, and 4-[Br-76]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging. J. Med. Chem., 2007, 50(5), 1028-1040.
40. Zhao, Q.H.; Tolmachev, V.; Carlsson, J.; Lundqvist, H.; Sundin, J.; Janson, J.C.; Sundin, A. Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF. Bioconjug. Chem., 1999, 10(6), 938-946.
41. 76Br]4-bromodexetimide. J. Nucl. Med., 1999, 40(6), 935-941.
42. Bruehlmeier, M.; Roelcke, U.; Blauenstein, P.; Missimer, J.; Schubiger, P.A.; Locher, J.T.; Pellikka, R.; Ametamey, S.M. Measurement of the extracellular space in brain tumors using Br-76-bromide and PET. J. Nucl. Med., 2003, 44(8), 1210-1218.
43. 55Co-EDTA for renal imaging using positron emission tomography (PET): a feasibility study. Nucl. Med. Biol., 2000, 27(1), 77-81.
44. Jansen, H.M.; Knollema, S.; van der Duin, L.V.; Willemsen, A.T.; Wiersma, A.; Franssen, E.J.; Russel, F.G.; Korf, J.; Paans, A.M., Pharmacokinetics and dosimetry of cobalt-55 and cobalt-57. J. Nucl. Med., 1996, 37 (12), 2082-2086.
45. Stevens, H.; Jansen, H.M.L.; DeReuck, J.; Lemmerling, M.; Strijckmans, K.; Goethals, P.; Lemahieu, I.; DeJong, B.M.; Willemsen, A.T.M.; Korf, J. Co-55-PET in stroke: relation to bloodflow, oxygen metabolism and gadolinium-MRI. Acta Neurol. Belg., 1997, 97(3), 172-177.
46. Jansen, H.M.; Pruim, J.; vd Vliet, A.M.; Paans, A.M.; Hew, J.M.; Franssen, E.J.; de Jong, B.M.; Kosterink, J.G.; Haaxma, R.; Korf, J. Visualization of damaged brain tissue after ischemic stroke with cobalt-55 positron emission tomography. J. Nucl. Med., 1994, 35(3), 456-460.
47. De Reuck, J.; Stevens, H.; Jansen, H.; Keppens, J.; Strijckmans, K.; Goethals, P.; Lemahieu, I.; Santens, P.; Korf, J. The significance of cobalt-55 positron emission tomography in ischemic stroke. J. Stroke Cerebrovasc. Dis., 1999, 8(1), 17-21.
48. 55Cobalt (Co) as a PET-tracer in stroke, compared with blood flow, oxygen metabolism, blood volume and gadolinium-MRI. J. Neurol. Sci., 1999, 171(1), 11-18.
49. De Reuck, J.; Stevens, H.; Jansen, H.; Keppens, J.; Strijckmans, K.; Goethals, P.; Lemahieu, I.; Santens, P.; Korf, J. Cobalt-55 positron emission tomography of ipsilateral thalamic and crossed cerebellar hypometabolism after supratentorial ischaemic stroke. Cerebrovasc. Dis., 1999, 9(1), 40-44.
50. 55Co-PET in stroke: relation to bloodflow, oxygen metabolism and gadolinium-MRI. Acta Neurol. Belg., 1997, 97(3), 172-177.
51. Jansen, H.M.; Paans, A.M.; vd Vliet, A.M.; Veenma-van der Duin, L.; Bolwijn-Meijer, C.J.; Pruim, J.; Willemsen, A.T.; Franssen, E.J.; Minderhoud, J.M.; Korf, J. Cobalt-55 positron emission tomography in ischemic stroke. Clin. Neurol. Neurosurg., 1997, 99(1), 6-10.
52. De Reuck, J.; Paemeleire, K.; Santens, P.; Strijckmans, K.; Lemahieu, I. Cobalt-55 positron emission tomography in symptomatic atherosclerotic carotid artery disease: borderzone versus territorial infarcts. Clin. Neurol. Neurosurg., 2004, 106(2), 77-81.
53. De Reuck, J.; Santens, P.; Strijckmans, K.; Lemahieu, I. Cobalt-55 positron emission tomography in vascular dementia: significance of white matter changes. J. Neurol. Sci., 2001, 195(1), 1-6.
54. De Reuck, J.; Vonck, K.; Santens, P.; Boon, P.; De Bleecker, J.; Strijckmans, K.; Lemahieu, I. Cobalt-55 positron emission tomography in late-onset epileptic seizures after thrombo-embolic middle cerebral artery infarction. J. Neurol. Sci., 2000, 181(1-2), 13-18.
55. De Reuck, J.; Santens, P.; Keppens, J.; De Bleecker, J.; Strijckmans, K.; Goethals, P.; Lemahieu, I.; Korf, J. Cobalt-55 positron emission tomography in recurrent ischaemic stroke. Clin. Neurol. Neurosurg., 1999, 101(1), 15-18.
56. Jansen, H.M.; Decoo, D.; Minderhoud, J.M. Co-registration of PET and MRI in different courses of MS using Cobalt-55 as a Calcium-tracer. Acta Neurol. Belg., 1997, 97(3), 178-182.
57. Jansen, H.M.; Willemsen, A.T.; Sinnige, L.G.; Paans, A.M.; Hew, J.M.; Franssen, E.J.; Zorgdrager, A.M.; Pruim, J.; Minderhoud, J.M.; Korf, J. Cobalt-55 positron emission tomography in relapsing-progressive multiple sclerosis. J. Neurol. Sci., 1995, 132(2), 139-145.
58. Jansen, H.M.; Dierckx, R.A.; Hew, J.M.; Paans, A.M.; Minderhoud, J.M.; Korf, J. Positron emission tomography in primary brain tumours using cobalt-55. Nucl. Med. Commun., 1997, 18(8), 734-740.
59. Linder, M.C. Biochemistry of Copper. Plenum Press: New York, 1991.
60. Karlin, K.P.; Zubieta, J. Copper Coordiantion Chemistry: Biochemical and Inorganic Perspectives, Adenine Press: New York, 1983.
61. Owen, C.A. Biochemical Aspects of Copper: Copper Proteins, Ceruloplasmin, and Copper Protein Binding, Noyes Publications: New Jersey, 1982.
62. Owen, C.A. Wilson's Disease: The Etiology, Clinical Aspects, and Treatment of Inherited Copper Toxicosis, Noyes: Park Ridge, NJ, 1981.
63. Lee, J.; Pena, M.M.O.; Nose, Y.; Thiele, D.J. Biochemical characterization of the human copper transporter CTR1. J. Biol. Chem., 2002, 277, 4380-4387.
64. Hamza, I.; Schaefer, M.; Klomp, L.W.; Gitlin, J.D. Interaction of the copper chaperone HAH1 with the Wilson disease protein is essential for copper homeostasis. Proc. Nat. Acad. Sci. USA, 1999, 96, 13363-13368.
65. Sun, X.; Anderson, C.J. Production and applications of copper-64 radiopharmaceuticals. Methods Enzymol., 2004, 386, 237-261.
66. 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32(7), 764-770.
67. McCarthy, D.W.; Bass, L.A.; Cutler, P.D.; Shefer, R.E.; Klinkowstein, R.E.; Herrero, P.; Lewis, J.S.; Cutler, C.S.; Anderson, C.J.; Welch, M.J. High purity production and potential applications of copper-60 and copper-61. Nucl. Med. Biol., 1999, 26(4), 351-358.
68. 60Cu-ATSM PET scan. Dis. Colon Rectum., 2007, 50(5), 780-780.
69. 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J. Nucl. Med., 2008, 49(2), 201-205.
70. 60Cu-ATSM in cancer of the uterine cervix. J. Nucl. Med., 2008, 49(7), 1177-1182.
71. natZn at a medical cyclotron. Appl. Radiat. Isot., 2006, 64(12), 1563-1573.
72. Fukumura, T.; Okada, K.; Szelecsenyi, F.; Kovacs, Z.; Suzuki, K. Practical production of Cu-61 using natural Co target and its simple purification with a chelating resin for Cu-61-ATSM. Radiochim. Acta, 2004, 92(4-6), 209-214.
73. 61Cu-DOTA-HSA as a blood pool agent. Appl. Radiat. Isot., 2009, 67(4), 511-515.
74. Tolmachev, V.; Lundqvist, H.; Einarsson, L. Production of Cu-61 from a natural nickel target. Appl. Radiat. Isot., 1998, 49(1-2), 7981.
75. McCarthy, D.W.; Bass, L.A.; Cutler, P.D.; Shefer, R.E.; Klinkowstein, R.E.; Herrero, P.; Lewis, J.S.; Cutler, C.S.; Anderson, C.J.; Welch, M.J. High purity production and potential applications of copper-60 and copper-61. Nucl. Med. Biol., 1999, 26(4), 351-358.
76. Yagi, M.; Kondo, K. Cu-62 Generator. Int. J. Appl. Radiat. Isot., 1979, 30(9), 569-570.
77. Robinson, G.D., Jr.; Zielinski, F.W.; Lee, A.W. The zinc- 62/copper-62 generator: a convenient source of copper-62 for radiopharmaceuticals. Int. J. Appl. Radiat. Isot., 1980, 31(2), 111-116.
78. Fujibayashi, Y.; Matsumoto, K.; Yonekura, Y.; Konishi, J.; Yokoyama, A. A New Zinc-62 Copper-62 Generator as a Copper-62 Source for Pet Radiopharmaceuticals. J. Nucl. Med., 1989, 30(11), 1838-1842.
79. 62Cu generator based on a cation exchanger and its fully remote-controlled preparation for clinical use. Nucl. Med. Biol., 2006, 33(6), 821-827.
80. 62Cu-ETS. Clin. Positron Imaging, 1999, 2(6), 317.
81. 62Cu generator. AJR Am. J. Roentgenol., 2008, 190(2), 427-432.
82. Fujibayashi, Y.; Taniuchi, H.; Yonekura, Y.; Ohtani, H.; Konishi, J.; Yokoyama, A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nucl. Med., 1997, 38(7), 1155-1160.
83. Anderson, C.J.; Connett, J.M.; Schwarz, S.W.; Rocque, P.A.; Guo, L.W.; Philpott, G.W.; Zinn, K.R.; Meares, C.F.; Welch, M.J. Copper-64-labeled antibodies for PET imaging. J. Nucl. Med., 1992, 33(9), 1685-1691.
84. Anderson, C.J.; Rocque, P.A.; Weinheimer, C.J.; Welch, M.J. Evaluation of copper-labeled bifunctional chelate-albumin conjugates for blood pool imaging. Nucl. Med. Biol., 1993, 20, 461-467.
85. Anderson, C.J.; Welch, M.J., Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem. Rev., 1999, 99, 22192234.
86. 64Cu-TETA-Octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med., 2001, 42, 213-221.
87. 64Cu-labeled bombesin analogue. Bioconjug. Chem., 2003, 14(4), 756-763.
88. Philpott, G.W.; Schwarz, S.W.; Anderson, C.J.; Dehdashti, F.; Connett, J.M.; Zinn, K.R.; Meares, C.F.; Cutler, P.D.; Welch, M.J.; Siegel, B.A. RadioimmunoPET: Detection of colorectal carinoma with positron-emitting copper-64-labeled monoclonal antibody. J. Nucl. Med., 1995, 36, 1818-1824.
89. Li, W.P.; Lewis, J.S.; Kim, J.; Bujas, J.E.; Johnson, M.A.; Erion, J.L.; Anderson, C.J. DOTA-D-Tyr1-Octreotate: A somastostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. Bioconjug. Chem., 2002, 13, 721-728.
90. Wadas, T.J.; Anderson, C.J. Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat. Protoc., 2006, 1(6), 3062-3068.
91. Sun, X.; Kim, J.; Martell, A.E.; Welch, M.J.; Anderson, C.J. In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands. Nucl. Med. Biol., 2004, 31(8), 1051-1059.
92. Smith, S.V., Molecular imaging with copper-64. J. Inorg. Biochem., 2004, 98(11), 1874-1901.
93. Anderson, C.J.; Jones, L.A.; Bass, L.A.; Sherman, E.L.C.; McCarthy, D.W.; Cutler, P.D.; Lanahan, M.V.; Cristel, M.E.; Lewis, J.S.; Schwarz, S.W. Radiotheraphy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J. Nucl. Med., 1998, 39, 1944-1951.
94. 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin. Cancer Res., 1999, 5, 3608-3616.
95. Lewis, J.S.; Laforest, R.; Lewis, M.R.; Anderson, C.J. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model. Cancer Biother. Radiopharm., 2000, 15(6), 593-604.
96. 67/64Cu-labeled anti-Li-CAM antibody chCE7: selection of copper ligands and PET imaging. Nucl. Med. Biol., 2003, 30(4), 417-427.
97. Connett, J.M.; Anderson, C.J.; Guo, L.W.; Schwarz, S.W.; Zinn, K.R.; Rogers, B.E.; Siegel, B.A.; Philpott, G.W.; Welch, M.J. Radioimmunotherapy with a Cu-64-labeled monoclonal antibody: A comparison with Cu-67. Proc. Natl. Acad. Sci. USA, 1996, 93, 6814-6818.
98. Anderson, C.J.; Schwarz, S.W.; Connett, J.M.; Cutler, P.D.; Guo, L.W.; Germain, C.J.; Philpoyy, G.W.; Zinn, K.R.; Greiner, D.P.; Meares, C.F. Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab')2. J. Nucl. Med., 1995, 36(5), 850-858.
99. McCarthy, D.W.; Shefer, R.E.; Klinkowstein, R.E.; Bass, L.A.; Margenau, W.H.; Cutler, C.S.; Anderson, C.J.; Welch, M.J. The efficient production of high specific activity Cu-64 using a biomedical cyclotron. Nucl. Med. Biol., 1997, 24, 35-43.
100. Busch, D.H. The compleat coordination chemistry. one practitioner's perspective. Chem.Rev., 1993, 93, 847-860.
101. Moi, M.K.; Meares, C.F.; McCall, M.J.; Cole, W.C.; DeNardo, S.J. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal. Biochem., 1985, 148, 249-253.
102. 57Co. Int. J. Rad. Appl. Instrum. B., 1986, 13(4), 363-368.
103. Cole, W.C.; DeNardo, S.J.; Meares, C.F.; McCall, M.J.; DeNardo, G.L.; Epstein, A.L.; O'Brien, H.A.; Moi, M.K. Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J. Nucl. Med., 1987, 28(1), 83-90.
104. Anderson, C.J.; Rocque, P.A.; Weinheimer, C.J.; Welch, M.J. Evaluation of copper-labeled bifunctional chelate-albumin conjugates for blood pool imaging. Nucl. Med. Biol., 1993, 20, 461-467.
105. 67Cu-2IT-Lym-1 for non-hodgkin's lymphoma. J. Nucl. Med., 1999, 40, 2014-2020.
106. Anderson, C.J.; Dehdashti, F.; Cutler, P.D.; Schwarz, S.W.; Laforest, R.; Bass, L.A.; Lewis, J.S.; McCarthy, D.W. Copper-64-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med., 2001, 42, 213-221.
107. 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl. Med. Biol., 1999, 26, 841-845.
108. Bass, L.A.; Wang, M.; Welch, M.J.; Anderson, C.J. In vivo Transchelation of Copper-64 from TETA-octreotide to Superoxide Dismutase in Rat Liver. Bioconjugate Chem., 2000, 11, 527-532.
109. Boswell, C.A.; Sun, X.; Niu, W.; Weisman, G.R.; Wong, E.H.; Rheingold, A.L.; Anderson, C.J. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacro-cyclic complexes. J. Med. Chem., 2004, 47(6), 1465-1474.
110. Sprague, J.E.; Peng, Y.; Sun, X.; Weisman, G.R.; Wong, E.H.; Achilefu, S.; Anderson, C.J. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin. Cancer Res., 2004, 10(24), 8674-8682.
111. Wong, E.H.; Weisman, G.R.; Hill, D.C.; Reed, D.P.; Rogers, M.E.; Condon, J.S.; Fagan, M.; Calabrese, J.C.; Lam, K.-C.; Guzei, I.A.; Rheingold, A.L. Synthesis and characterization of cross-bridged cyclams and pendant-armed derivatives and structural studies of their copper(II) complexes. J. Am. Chem. Soc., 2000, 122, 10561-10572.
112. 2+ complexe with a tetraaza macrocyclic tetraacetate. Acta Cryst., 1988, C44, 1740-1742.
113. Sun, X.; Wuest, M.; Weisman, G.R.; Wong, E.H.; Reed, D.P.; Boswell, C.A.; Motekaitis, R.; Martell, A.E.; Welch, M.J.; Anderson, C.J. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J. Med. Chem., 2002, 45(2), 469-477.
114. 64CuCl2. J. Nucl. Med., 2006, 47(10), 1649-1652.
115. 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency. Bioconjug. Chem., 2008, 19(6), 1256-1268.
116. 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J. Nucl. Med., 2008, 49(5), 830-836.
117. 68Ga. Nucl. Med. Biol., 2009, 36(1), 3945.
118. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl. Med. Commun., 2009, 30(4), 281-286.
119. Khan, M.U.; Khan, S.; El-Refaie, S.; Win, Z.; Rubello, D.; Al-Nahhas, A., Clinical indications for Gallium-68 positron emission tomography imaging. Eur. J. Surg.Oncol., 2009, 35(6), 561-567.
120. 18F-radiopharmacy. Ernst. Schering Res. Found Workshop, 2007, (62), 215-242.
121. Al-Nahhas, A.; Win, Z.; Szyszko, T.; Singh, A.; Nanni, C.; Fanti, S.; Rubello, D. Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res., 2007, 27(6B), 4087-4094.
122. Al-Nahhas, A.; Win, Z.; Szyszko, T.; Singh, A.; Khan, S.; Rubello, D. What can gallium-68 PET add to receptor and molecular imaging? Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(12), 1897-1901.
123. Lambrecht, R.M.; Sajjad, M. Cyclotron Isotopes and Radiophar-maceuticals.38. Accelerator-Derived Radionuclide Generators. Radiochim. Acta, 1988, 43(3), 171-179.
124. Ehrhardt, G.J.; Welch, M.J. A new germanium-63/gallium-68 generator. J. Nucl. Med., 1978, 19(8), 925-929.
125. Mirzadeh, S.; Lambrecht, R.M. Radiochemistry of germanium. J. Radioan Nucl. Ch Ar., 1996, 202(1-2), 7-102.
126. 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjug. Chem., 2008, 19(2), 569-573.
127. 68Ga-labeled peptide. Nucl. Med. Biol., 2008, 35(5), 529-536.
128. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem., 2002, 13(3), 530-541.
129. 68Ga-labelled DOTA-derivatised peptide ligands. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(8), 1097-1104.
130. 68Ga. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32(4), 478-485.
131. Antunes, P.; Ginj, M.; Zhang, H.; Waser, B.; Baum, R.P.; Reubi, J.C.; Maecke, H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(7), 982-993.
132. 68Ga-labelled peptides. Nucl. Med. Commun., 2007, 28(11), 870-875.
133. 68Ga citrate for routine clinical PET. Nucl. Med. Commun., 2009, 30(7), 542-545.
134. Asti, M. D.P.G.; Fraternali; A.; Grassi, E.; Sghedoni, R.; Fioroni, F.; Roesch, F.; Versari, A.; Salvo, D. Validation of (68)Ge/(68)Ga generator processing by chemical purification for routine clinical application of (68)Ga-DOTATOC. Nucl. Med. Biol., 2008, 35(6), 721-724.
135. 68Ga]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J. Nucl. Med., 2001, 42(7), 1053-1056.
136. 67Ga-labeled antibody via 1B4M or C-NOTA chelates. Nucl. Med. Biol., 1997, 24(3), 225-230.
137. Harris, W.R. Estimation of the ferrous-transferrin binding constants based on thermodynamic studies of nickel(II)-transferrin. J. Inorg. Biochem., 1986, 27(1), 41-52.
138. Harris, W.R. Thermodynamic binding constants of the zinc-human serum transferrin complex. Biochemistry, 1983, 22(16), 3920-3926.
139. Prata;, M.I.M.; Santos;, A.C.; Geraldes;, C.F.G.C.; Limaa, J.J.P.d. Structural and in vivo studies of metal chelates of Ga(III) relevant to biomedical imaging. J. Inorg. Biochem., 2000, 79(1-4), 359-363.
140. Broan, J.P.; Cox, L.; Craig, A.S.; Kataky, R.; Parker, D.; Harrison, A.; Randall, M.; Ferguson, G. Structure and solution stability of indium and gallium complexes of 1,4,7-triazacyclononanetriacetate and of yttrium complexes of 1,4,7,10-tetraazacyclododecane-tetraacetate and related ligands: Kinetically stable complexes for use in imaging and radioimmunotherapy. J. Chem. Soc. Perkin Trans., 1991, 2, 87-89.
141. 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor- targeted PET radiopharmaceuticals. Nucl. Med. Biol., 2003, 30 (7), 725-731.
142. 66Ga as an isotope for PET imaging and quantification. Med. Phys., 1997, 24(2), 317-326.
143. 67Ga at a compact cyclotron. Acta. Radiol., (Suppl), 1991, 376, 62-63.
144. 66Ga-- a promising isotope for [165] positron emission tomography. Acta Radiol., (Suppl), 1991, 376, 61.
145. 66Ga and labeling of antimyosin antibody for positron imaging of acute myocardial infarction. Eur. J. Nucl. Med., 1990, 16(4-6), 237-240.
146. 66Ga as a positron emitting label of albumin colloids for clinical use. Eur. J. Nucl. Med., 1988, 14, (3), 152-154.
147. Stocklin, G., Bromine-77 and iodine-123 radiopharmaceuticals. Int J Appl Radiat Isot., 1977, 28, (1-2), 131-147.
148. Seevers, R.H.; Counsell, R.E. Radioiodination techniques for small organic-molecules. Chem. Rev., 1982, 82(6), 575-590.
149. Grassi, J.; Pradelles, P. Radioiodination and Other Labelling Techniques. Springer-Verlag: Berlin Heidelberg. New York, 1987.
150. Wilbur, D.S. Radiohalogenation of proteins - an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjug. Chem., 1992, 3(6), 433-470.
151. Salacinski, P.R.P.; Mclean, C.; Sykes, J.E.C.; Clementjones, V.V.; Lowry, P.J. Iodination of Proteins, Glycoproteins, and Peptides Using a Solid-Phase Oxidizing-Agent, 1,3,4,6-Tetrachloro-3-Alpha 6-Alpha-Diphenyl Glycoluril (Lodogen). Anal. Biochem., 1981, 117, (1), 136-146.
152. Greenwood, F.C.; Hunter, W.M.; Glover, J.S. Citation Classics -Preparation of I-131-Labelled Human Growth-Hormone of High Specific Radioactivity. Curr. Contents, 1977, (15), 12-12.
153. Hunter, W.M.; Greenwood, F.C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature, 1962, 194, 495-496.
154. Markwell, M.A. A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum. Anal. Biochem., 1982, 125(2), 427-432.
155. Russell, J.; O'Donoghue, J.A.; Finn, R.; Koziorowski, J.; Ruan, S.; Humm, J.L.; Ling, C.C. Iodination of annexin V for imaging apoptosis. J. Nucl. Med., 2002, 43(5), 671-677.
156. Behr, T.M.; Gotthardt, M.; Becker, W.; Behe, M. Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Gottingen/Marburg experience. Nuklearmedizin, 2002, 41(2), 71-79.
157. Rudinger, J.; Ruegg, U. Appendix: Preparation of N-succinimidyl 3-(4-hydroxyphenyl)propionate. Biochem. J., 1973, 133(3), 538-539.
158. 125I-containing acylating agent. Biochem. J., 1973, 133(3), 529-539.
159. Wilbur, D.S.; Hadley, S.W.; Hylarides, M.D.; Abrams, P.G.; Beaumier, P.A.; Morgan, A.C.; Reno, J.M.; Fritzberg, A.R. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J. Nucl. Med., 1989, 30(2), 216-226.
160. Wilbur, D.S. Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjug. Chem., 1992, 3(6), 433-470.
161. Eschmann, S.M.; Reischl, G.; Bilger, K.; Kupferschlager, J.; Thelen, M.H.; Dohmen, B.M.; Besenfelder, H.; Bares, R. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29(6), 760-767.
162. 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J. Nucl. Med., 2008, 49(6), 1017-1023.
163. 124I-PET in patients with differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(5), 958-965.
164. 124I PET. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(3), 502-508.
165. Lewis, J.S.; Welch, M.J.; Tang, L. Workshop on the production, application and clinical translation of ''non-standard'' PET nuclides: a meeting report. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(2), 101-106.
166. Larson, S.M.; Schoder, H. Advances in positron emission tomography applications for urologic cancers. Curr. Opin. Urol., 2008, 18(1), 65-70.
167. Lubberink, M.; Abdul Fatah, S.; Brans, B.; Hoekstra, O.S.; Teule, G.J. The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(1), 30-36.
168. Welch, M.J.; Laforest, R.; Lewis, J.S. Production of non-standard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides. Ernst Schering Res. Found Workshop, 2007, (62), 159-181.
169. DeNardo, S.J. Radioimmunodetection and therapy of breast cancer. Semin. Nucl. Med., 2005, 35(2), 143-151.
170. Glaser, M.; Luthra, S.K.; Brady, F. Applications of positron- emitting halogens in PET oncology (Review). Int. J.Oncol., 2003, 22(2), 253-267.
171. Lundqvist, H.; Tolmachev, V. Targeting peptides and positron emission tomography. Biopolymers, 2002, 66(6), 381-392.
172. Smith, M.F. Advances in rubidium PET and integrated imaging with CT angiography. Curr. Cardiol. Rep., 2008, 70(2), 135-141.
173. Gibbons, R.J.; Chareonthaitawee, P. Establishing the prognostic value of Rb-82 PET myocardial perfusion imaging: a step in the right direction. JACC Cardiovasc. Imaging, 2009, 2(7), 855-857.
174. Tang, J.; Rahmim, A.; Lautamaki, R.; Lodge, M.A.; Bengel, F.M.; Tsui, B.M. Optimization of Rb-82 PET acquisition and reconstruction protocols for myocardial perfusion defect detection. Phys. Med. Biol., 2009, 54(10), 3161-3171.
175. Alvarez-Diez, T.M.; deKemp, R.; Beanlands, R.; Vincent, J. Manufacture of strontium-82/rubidium-82 generators and quality control of rubidium-82 chloride for myocardial perfusion imaging in patients using positron emission tomography. Appl. Radiat. Isot., 1999, 50(6), 1015-1023.
176. Yano, Y.; Chu, P.; Budinger, T.F.; Grant, P.M.; Ogard, A.E.; Barnes, J.W.; O'Brien, H.A., Jr.; Hoop, B., Jr. Rubidium-82 generators for imaging studies. J. Nucl. Med., 1977, 18(1), 46-50.
177. Uddin, M.S.; Baba, M. Proton-induced activation cross-sections of the short-lived radionuclides formation on molybdenum. Appl. Radiat. Isot., 2008, 66(2), 208-214.
178. Bigott, H.M.; Laforest, R.; Liu, X.; Ruangma, A.; Wuest, F.; Welch, M.J. Advances in the production, processing and microPET image quality of technetium-94m. Nucl. Med. Biol., 2006, 33(7), 923-933.
179. 99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging disialoganglioside G(D2)-positive tumors. Nucl. Med. Biol., 1999, 26(6), 681-686.
180. Stone, C.K.; Christian, B.T.; Nickles, R.J.; Perlman, S.B. Technetium 94m-labeled methoxyisobutyl isonitrile: dosimetry and resting cardiac imaging with positron emission tomography. J. Nucl. Cardiol., 1994, 1(5 Pt 1), 425-433.
181. Nickles, R.J.; Nunn, A.D.; Stone, C.K.; Christian, B.T. Technetium-94m-teboroxime: synthesis, dosimetry and initial PET imaging studies. J. Nucl. Med., 1993, 34(7), 1058-1066.
182. Qaim, S.M. Production of high purity (94m)Tc for positron emission tomography studies. Nucl. Med. Biol., 2000, 27(4), 323-328.
183. 94mTc from enriched molybdenum targets and its large-scale production for nuclear medical application. Radiochim. Acta, 1994, 64, 113-120.
184. Bigott, H.M.; Prior, J.L.; Piwnica-Worms, D.R.; Welch, M.J. Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi. Mol. Imaging, 2005, 4(1), 30-39.
185. Bigott, H.M.; Parent, E.; Luyt, L.G.; Katzenellenbogen, J.A.; Welch, M.J. Design and synthesis of functionalized cyclopenta-dienyl tricarbonylmetal complexes for technetium-94m PET imaging of estrogen receptors. Bioconjug Chem., 2005, 16(2), 255-264.
186. Luyt, L.G.; Bigott, H.M.; Welch, M.J.; Katzenellenbogen, J.A. 7alpha- and 17alpha-substituted estrogens containing tridentate tricarbonyl rhenium/technetium complexes: synthesis of estrogen receptor imaging agents and evaluation using microPET with technetium-94m. Bioorg. Med. Chem., 2003, 11(23), 4977-4989.
187. Tang, J.; Rahmim, A.; Lautamaki, R.; Lodge, M.A.; Bengel, F.M.; Tsui, B.M.W. Optimization of Rb-82 PET acquisition and reconstruction protocols for myocardial perfusion defect detection. Phys. Med. Biol., 2009, 54(10), 3161-3171.
188. Rogers, B.E.; Parry, J.J.; Andrews, R.; Cordopatis, P.; Nock, B.A.; Maina, T. MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and (94m)Tc-Demotate 1. J. Nucl. Med., 2005, 46(11), 1889-1897.
189. Esmaeli, B.; McLaughlin, P.; Pro, B.; Samaniego, F.; Gayed, I.; Hagemeister, F.; Romaguera, J.; Cabanillas, F.; Neelapu, S.S.; Banay, R.; Fayad, L.; Wayne Saville, M.; Kwak, L.W. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann. Oncol., 2009, 20(4), 709-714.
190. Jimenez-Bonilla, J.F.; Quirce, R.; Banzo, I.; Martinez-Rodriguez, I.; Sainz-Esteban, A.; Barragan, J.E.; Lopez-Cordovilla, J.J.; Carril, J.M. In-111 ibritumomab scintigraphy (planar and SPECT) and FDG PET/CT before Y-90 ibritumomab treatment in a patient with mantle cell lymphoma. Clin. Nucl. Med., 2007, 32(12), 952-953.
191. Crow, D.M.; Williams, L.; Colcher, D.; Wong, J.Y.; Raubitschek, A.; Shively, J.E. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. Bioconjug Chem., 2005, 16(5), 1117-1125.
192. Denardo, S.J.; Richman, C.M.; Kukis, D.L.; Shen, S.; Lamborn, K.R.; Miers, L.A.; Kroger, L.A.; Perez, E.A.; Denardo, G.L. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. Anticancer Res., 1998, 18(6A), 4011-4018.
193. Dillehay, L.E.; Mayer, R.; Zhang, Y.G.; Song, S.Y.; Shao, Y.; Mackensen, D.G.; Williams, J.R. Use of bremsstrahlung radiation to monitor Y-90 tumor and whole body activities during experimental radioimmunotherapy in mice. Cancer, 1994, 73(3 Suppl), 945-950.
194. Leichner, P.K.; Order, S.E.; Klein, J.L. Y-90 antiferritin dosimetry in hepatoma. Int. J. Radiat. Oncol. Biol. Phys., 1989, 17(1), 241.
195. Stewart, J.S.; Hird, V.; Epenetos, A.A. Alternative to toxicity and dosimetry of Y-90 labeled antibody. Int. J. Radiat. Oncol. Biol. Phys., 1989, 17(1), 241.
196. 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma]. Kaku Igaku., 2008, 45(2), 99-113.
197. 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma. Hell J. Nucl. Med., 2008, 11(1), 12-15.
198. 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience. Radiology, 2008, 246(3), 895-902.
199. Grillo-Lopez, A.J. Monoclonal antibody therapy for B-cell lymphoma. Int. J. Hematol., 2002, 76(5), 385-393.
200. Grillo-Lopez, A.J. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev. Anticancer Ther., 2002, 2(5), 485-493.
201. Chakraborty, S.; Unni, P.R.; Banerjee, S.; Samuel, G.; Das, T.; Sarma, H.D.; Ramamoorthy, N.; Pillai, M.R. Potential (166)Ho radiopharmaceuticals for intravascular radiation therapy (IVRT)-I: [(166)Ho] holmium labeled ethylene dicysteine. Nucl. Med. Biol., 2001, 28(3), 309-317.
202. Banerjee, S.; Samuel, G.; Kothari, K.; Unni, P.R.; Sarma, H.D.; Pillai, M.R. Tc-99m and Re-186 complexes of tetraphosphonate ligands and their biodistribution pattern in animal models. Nucl. Med. Biol., 2001, 28(2), 205-213.
203. 186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation. Nucl. Med. Biol., 2001, 28(6), 709-717.
204. de Ligny, C.L.; Gelsema, W.J.; Tji, T.G.; Huigen, Y.M.; Vink, H.A. Bone seeking pharmaceuticals. Int. J. Rad. Appl. Instrum. B, 1990, 17(2), 161-179.
205. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Int. J. Rad. Appl. Instrum. B, 1987, 14(3), 223-232.
206. Logan, K.W.; Volkert, W.A.; Holmes, R.A. Radiation dose calculations in persons receiving injection of samarium-153 EDTMP. J. Nucl. Med., 1987, 28(4), 505-509.
207. Jurisson, S.; Berning, D.; Jia, W.; Ma, D. Coordination compounds in nuclear medicine. Chem. Rev., 1993, 93(3), 1137-1156.
208. Bayouth, J.E.; Macey, D.J.; Boyer, A.L.; Champlin, R.E. Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation. Med. Phys., 1995, 22(6), 743-753.
209. Bayouth, J.E.; Macey, D.J.; Kasi, L.P.; Garlich, J.R.; McMillan, K.; Dimopoulos, M.A.; Champlin, R.E. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J. Nucl. Med., 1995, 36(5), 730-737.
210. Volkert, W.A.; Hoffman, T.J. Therapeutic radiopharmaceuticals. Chem. Rev., 1999, 99, 2269-2292.
211. Parks, N.J.; Kawakami, T.G.; Avila, M.J.; White, R.; Cain, G.R.; Raaka, S.D.; Hornoff, W.; Fisher, P.; Moore, P. Bone marrow transplantation in dogs after radioablation with a new holmium-166 amino phosphonic acid bone-seeking agent (DOTMP). Blood, 1993, 82(1), 318-325.
212. Conzone, S.D.; Haifeli, U.O.; Day, D.E.; Ehrhardt, G.J. Preparation and properties of radioactive rhenium glass microspheres intended for in vivo radioembolization therapy. J. Biomed. Mater. Res., 1998, 42(4), 617-625.
213. Cutler, C.S.; Smith, C.J.; Ehrhardt, G.J.; Tyler, T.T.; Jurisson, S.S.; Deutsch, E. Current and potential therapeutic uses of lanthanide radioisopotes. CancerBiother. Radiopharm., 2000, 15(6), 531-545.
214. 86Y for PET imaging. Appl. Radiat. Isot., 2009, 67(1), 710.
215. Yoo, J.; Tang, L.; Perkins, T.A.; Rowland, D.J.; Laforest, R.; Lewis, J.S.; Welch, M.J. Preparation of high specific activity (86)Y using a small biomedical cyclotron. Nucl. Med. Biol., 2005, 32(8), 891-897.
216. 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J. Med. Chem., 2005, 48(8), 2985-2992.
217. Perk, L.R.; Vosjan, M.J.; Visser, G.W.; Budde, M.; Jurek, P.; Kiefer, G.E.; van Dongen, G.A. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur. J. Nucl. Med. Mol. Imaging, 2009, 37(2),250-259.
218. Holland, J.P.; Sheh, Y.; Lewis, J.S. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol., 2009, 36(7), 729-739.
219. Borjesson, P.K.; Jauw, Y.W.; Boellaard, R.; de Bree, R.; Comans, E.F.; Roos, J.C.; Castelijns, J.A.; Vosjan, M.J.; Kummer, J.A.; Leemans, C.R.; Lammertsma, A.A.; van Dongen, G.A. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin. Cancer Res., 2006, 12(7 Pt 1), 2133-2140.
220. Verel, I.; Visser, G.W.; Boerman, O.C.; van Eerd, J.E.; Finn, R.; Boellaard, R.; Vosjan, M.J.; Stigter-van Walsum, M.; Snow, G.B.; van Dongen, G.A. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother. Radiopharm., 2003, 18(4), 655-661.
221. 89Zr for antibody labeling and positron emission tomography. J. Labelled Compd. Radiopharm., 1986, 23 1297-1298.
222. 89Zr-porphyrin for positron label of monoclonal antibodies. J. Labelled Compd. Radiopharm., 1991, 30, 326.
223. Meijs, W.E.; Haisma, H. J.; Klok, R. P.; van Gog, F. B.; Kievit, E.; Pinedo, H. M.; Herscheid, J. D. Zirconiumlabeled monoclonal antibodies and their distribution in tumorbearing nude mice. J. Nucl. Med., 1997, 38, 112-118.
224. Meijs, W.E.; Haisma, H. J.; Van der Schors, R.; Wijbrandts, R.; Van den Oever, K.; Klok, R. P.; Pinedo, H. M.; Herscheid, J.D. A facile method for the labeling of proteins with zirconium isotopes. Nucl. Med. Biol., 1996, 23, 439-448.
225. Verel, I.; Visser, G.W.; van Dongen, G.A. The promise of immuno-PET in radioimmunotherapy. J. Nucl. Med., 2005, 46(Suppl 1), 164S-171S.
226. Tai, Y.C.; Laforest, R. Instrumentation aspects of animal PET. Annu. Rev. Biomed. Eng., 2005, 7, 255-285.
227. Shokeen, M.; Fettig, N.M.; Rossin, R. Synthesis, in vitro and in vivo evaluation of radiolabeled nanoparticles. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(3), 267-277.
228. Fukukawa, K.; Rossin, R.; Hagooly, A.; Pressly, E.D.; Hunt, J.N.; Messmore, B.W.; Wooley, K.L.; Welch, M.J.; Hawker, C.J. Synthesis and characterization of core-shell star copolymers for in vivo PET imaging applications. Biomacromolecules, 2008, 9(4), 1329-1339.
229. VanBrocklin, H.F. Advancing molecular imaging from the laboratory to everyday practice. J. Nucl. Med., 2008, 49(12), 22N-23N.
230. VanBrocklin, H.F. Radiopharmaceuticals for Drug Development: United States Regulatory Perspective. Curr. Radiopharma., 2008, 1, 2-6.
231. Marchetti, S.; Schellens, J.H. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br. J. Cancer, 2007, 97(5), 577-581.
232. Lappin, G.; Kuhnz, W.; Jochemsen, R.; Kneer, J.; Chaudhary, A.; Oosterhuis, B.; Drijfhout, W.J.; Rowland, M.; Garner, R.C. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharmacol. Ther., 2006, 80(3), 203-215.